Chagas disease

What is Chagas disease?

Chagas disease, also known as American trypanosomiasis, is a potentially life-threatening infectious disease caused by the parasite Trypanosoma cruzi. This neglected tropical disease primarily affects people in Latin America, where an estimated 6-7 million people are currently infected. The disease is transmitted mainly through blood-sucking insects called triatomine bugs, but can also spread through blood transfusions, organ transplants, contaminated food, and from mother to child during pregnancy. While historically concentrated in rural Latin America, migration has brought Chagas disease to non-endemic countries worldwide.

Key statistics

Symptoms

Acute phase: Fever, fatigue, body aches, headache, rash, loss of appetite, diarrhea, vomiting, Romaña sign (eyelid swelling), chagoma (skin lesion at infection site).

Chronic phase: Irregular heartbeat, heart failure, sudden cardiac death, difficulty swallowing, severe constipation, abdominal pain.

The disease progresses through two distinct phases. The acute phase occurs within the first few weeks to months after infection and often goes unnoticed, as symptoms are mild and nonspecific, resembling a common viral illness. The characteristic Romaña sign—unilateral eyelid swelling—occurs in less than half of cases but is highly suggestive of Chagas disease when present. A chagoma, a reddish nodule at the site where the parasite entered through the skin, may also develop.

Submit Your Paper

Most people then enter an asymptomatic chronic phase that can last decades. However, 30-40% eventually develop serious complications affecting the heart, digestive system, or nervous system. Chronic Chagas cardiomyopathy is the most serious manifestation, leading to heart rhythm abnormalities, heart failure, and sudden cardiac death. Digestive complications include megaesophagus (enlarged esophagus) causing difficulty swallowing, and megacolon (enlarged colon) causing severe constipation and abdominal pain.

Causes and risk factors

Chagas disease is caused by infection with the parasite Trypanosoma cruzi. The primary transmission route is through the feces of infected triatomine bugs (also called “kissing bugs” or “vinchucas”), which typically bite exposed skin at night and defecate near the bite wound. The parasite enters the body when the person inadvertently rubs the infected feces into the bite wound, mucous membranes, or broken skin.

Risk factors include living in or visiting rural areas of Latin America where triatomine bugs are present, particularly in poorly constructed housing with thatched roofs, adobe walls, or other cracks where bugs can hide. Other transmission routes include receiving contaminated blood transfusions or organ transplants, consuming contaminated food or drinks (particularly fresh fruit juices), and mother-to-child transmission during pregnancy or childbirth. Laboratory workers handling infected materials also face occupational risk.

Prevention

Prevention focuses primarily on vector control and screening of blood supplies. In endemic areas, improving housing conditions by eliminating cracks in walls and roofs where triatomine bugs hide is highly effective. Insecticide spraying can reduce bug populations, though resistance is emerging. When traveling to endemic areas, sleep under insecticide-treated bed nets and avoid sleeping in mud, adobe, or thatched-roof buildings.

Universal screening of blood and organ donors has dramatically reduced transmission through transfusions and transplants in many countries. Pregnant women in endemic areas or with risk factors should be screened, as early treatment of infected newborns is highly effective. Food safety measures include avoiding consumption of fresh sugarcane or fruit juices in endemic areas unless pasteurized. Currently, no vaccine exists for Chagas disease, making vector control and screening programs essential prevention strategies.

Complications

Without treatment, Chagas disease can lead to severe, life-threatening complications decades after initial infection. Chronic Chagas cardiomyopathy affects 20-30% of infected individuals and is characterized by progressive heart muscle damage, leading to heart rhythm abnormalities, heart failure, blood clots, stroke, and sudden cardiac death. This cardiac involvement is the leading cause of death in Chagas disease.

Digestive complications affect 10-15% of patients, primarily in certain geographic regions. Megaesophagus causes progressive difficulty swallowing, malnutrition, aspiration pneumonia, and increased risk of esophageal cancer. Megacolon leads to severe constipation, intestinal obstruction, and potentially life-threatening complications requiring surgical intervention. Neurological manifestations, though less common, can include stroke due to cardiac complications and, rarely, meningoencephalitis in immunocompromised patients.

Diagnosis

Diagnosis varies by disease phase and requires specific laboratory testing. During the acute phase, direct microscopic examination of blood samples can detect the parasite, while polymerase chain reaction (PCR) testing offers higher sensitivity. However, acute infection is often missed due to mild symptoms and limited diagnostic suspicion.

Chronic phase diagnosis relies on serology, requiring at least two different serological tests such as enzyme-linked immunosorbent assay (ELISA), indirect immunofluorescence assay (IFA), or particle agglutination tests. The World Health Organization recommends using two tests with different antigenic preparations to confirm diagnosis due to potential cross-reactivity and false positives.

For cardiac assessment, electrocardiogram (ECG) may show characteristic changes including right bundle branch block and left anterior fascicular block. Echocardiography evaluates heart function and structure, while 24-hour Holter monitoring can detect dangerous arrhythmias. Chest X-ray may reveal cardiomegaly. For digestive complications, barium swallow studies demonstrate megaesophagus, while colonography or CT scanning can identify megacolon.

Treatment

Two antiparasitic medications are approved for treating Chagas disease: benznidazole and nifurtimox. Treatment is most effective during the acute phase and in children, where it can achieve parasitological cure rates exceeding 90%. Benznidazole is generally the first-line treatment due to better tolerability, typically given for 60 days in adults and 30-60 days in children.

In chronic phase disease, treatment benefits are more controversial but recent studies suggest antiparasitic therapy may slow or prevent progression of cardiac disease. Treatment decisions must weigh potential benefits against side effects, which can include skin rash, gastrointestinal symptoms, and peripheral neuropathy. Pregnant women and individuals with severe kidney or liver disease should avoid these medications.

Symptomatic treatment addresses complications: heart failure medications, pacemakers or implantable cardioverter-defibrillators for arrhythmias, anticoagulants for stroke prevention, and surgical interventions for severe digestive complications. Heart transplantation may be necessary for end-stage cardiac disease.

Prognosis

Prognosis varies significantly depending on the timing of diagnosis and treatment. Early treatment during acute infection or childhood typically results in parasitological cure and prevents chronic complications. Most people remain in the asymptomatic chronic phase throughout their lives, with normal life expectancy.

However, those who develop chronic cardiomyopathy face a more guarded prognosis, with 5-year survival rates of 50-80% depending on severity. Sudden cardiac death accounts for 55-65% of Chagas-related mortality. Patients with digestive complications generally have better outcomes, though megaesophagus increases aspiration risk and esophageal cancer risk. With appropriate medical management, many patients with chronic complications can maintain good quality of life for years.

Quality of life

Living with Chagas disease requires ongoing medical monitoring and lifestyle adjustments. Regular cardiology follow-up is essential, including annual ECGs and echocardiograms to monitor for progression. Patients should maintain heart-healthy habits: regular moderate exercise as tolerated, low-sodium diet, smoking cessation, and limited alcohol consumption.

Those with digestive complications may need dietary modifications, eating smaller, more frequent meals and avoiding foods that are difficult to swallow. Stress management and mental health support are important, as chronic illness anxiety and depression are common. Many patients benefit from joining support groups or connecting with others who have Chagas disease.

Employment considerations may arise for those with cardiac complications, particularly jobs requiring physical exertion or where sudden incapacitation could pose safety risks. However, many patients continue productive careers with appropriate accommodations and medical management.

Pregnancy and fertility

Chagas disease can be transmitted from mother to child during pregnancy, occurring in approximately 1-5% of pregnancies in infected women. All pregnant women with risk factors should be screened, and newborns of infected mothers require testing. Maternal-fetal transmission can occur throughout pregnancy but is most common during delivery.

Antiparasitic medications are contraindicated during pregnancy due to potential teratogenic effects. However, most pregnant women with chronic Chagas disease have uncomplicated pregnancies. Those with cardiac complications require specialized obstetric and cardiac care, as pregnancy can stress the cardiovascular system.

Newborns should be tested for infection, with follow-up testing at 8-12 months to allow maternal antibodies to clear. Infected newborns respond excellently to treatment, with cure rates approaching 100%. Breastfeeding is generally safe unless there are cracked or bleeding nipples.

Children

Children with Chagas disease have excellent treatment outcomes, with cure rates of 90-100% when treated appropriately. Diagnosis in children born to infected mothers requires careful timing, as maternal antibodies can persist for up to 12 months, potentially causing false-positive results.

Benznidazole is the preferred treatment in children, typically given for 30-60 days depending on age and weight. Side effects are generally milder in children than adults. Regular follow-up is essential to monitor treatment response and potential side effects.

School-age children can typically participate in normal activities during and after treatment. Education about the disease helps children understand their condition without causing unnecessary fear or stigma.

When to see a doctor

Seek immediate medical attention for chest pain, severe shortness of breath, fainting, or irregular heartbeat, especially in individuals with known Chagas disease. These symptoms may indicate serious cardiac complications requiring urgent intervention.

Routine medical care should be sought if you have risk factors for Chagas disease, including travel to or residence in endemic areas, receiving blood transfusions or organ transplants in Latin America before universal screening implementation, or having a mother from an endemic area. Early detection and treatment significantly improve outcomes.

Contact a healthcare provider if you develop fever, fatigue, and swelling around the eye after potential exposure to triatomine bugs. While acute Chagas disease is often mild, early diagnosis enables prompt treatment and prevents chronic complications.

Regional context

Chagas disease is not endemic to the Caucasus region (Georgia, Armenia, Azerbaijan) or the Eastern Mediterranean. However, cases may occur in immigrants from Latin America or travelers returning from endemic areas. Healthcare providers in these regions should maintain awareness of Chagas disease when evaluating patients with relevant exposure history and compatible symptoms.

We invite healthcare professionals and researchers from the Caucasus and Eastern Mediterranean regions to contribute their experiences with Chagas disease diagnosis and management to Global Medical Journal.

Research and clinical trials

Current research focuses on developing new treatments with improved efficacy and tolerability, diagnostic tools for monitoring treatment response, and potential vaccines. Several promising antiparasitic compounds are in clinical trials, including fexinidazole and fosravuconazole, which may offer shorter treatment courses and fewer side effects.

Diagnostic research emphasizes developing point-of-care tests for resource-limited settings and biomarkers to predict which patients will develop chronic complications. Vector control research investigates novel approaches including genetically modified triatomine bugs and biological control agents.

Patients interested in clinical trials can search ClinicalTrials.gov using terms “Chagas disease” or “Trypanosoma cruzi.” Participation in research studies contributes to advancing treatment options for future patients.

Frequently asked questions

Can Chagas disease be cured?

Yes, Chagas disease can be cured, especially when treated during the acute phase or in children. Treatment success rates exceed 90% in these groups. Even in chronic disease, treatment may prevent or slow progression of complications.

Is Chagas disease contagious between people?

Chagas disease is not contagious through casual contact, coughing, or sneezing. It spreads primarily through triatomine bug bites, contaminated blood products, organ transplants, contaminated food, or from mother to child during pregnancy.

Can I travel safely to areas where Chagas disease is common?

Yes, with proper precautions. Stay in well-constructed accommodations, use insecticide-treated bed nets, avoid sleeping in adobe or thatched-roof buildings, and consume only pasteurized juices and properly prepared foods.

Will I develop heart problems if I have Chagas disease?

Not necessarily. About 60-70% of people with chronic Chagas disease never develop complications. Among those who do, cardiac problems affect 20-30% of infected individuals, typically decades after initial infection.

Should my family members be tested for Chagas disease?

Family members should be tested if they have similar risk factors, such as living in the same endemic area or being born to an infected mother. Chagas disease doesn’t spread between family members through normal household contact.

Support and resources

• World Health Organization Chagas Disease: https://www.who.int/health-topics/chagas-disease
• Pan American Health Organization: https://www.paho.org/en/topics/chagas-disease
• Centers for Disease Control and Prevention: https://www.cdc.gov/parasites/chagas/
• Drugs for Neglected Diseases Initiative: https://dndi.org/diseases/chagas/
• Coalition Chagas: https://coalitionchagas.org/

Related conditions

African trypanosomiasis (sleeping sickness)
Leishmaniasis
Malaria
Dilated cardiomyopathy
Achalasia

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.